On August 21, 2023 AskGene Pharma Inc. reported that the first patient has been dosed at Columbia University Irving Medical Center in New York City in the phase I clinical trial of ASKG915 (Press release, AskGene Pharmaceuticals, AUG 21, 2023, View Source [SID1234634595]). The study is an open label, multi-regional phase I clinical trial evaluating the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent in patients with selected advanced solid tumors. ASKG915 is the first anti-PD-1/IL-15 prodrug in clinical development in the world.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Barbara Hickingbottom, J.D., M.D., Chief Medical Officer of AskGene commented: "Cytokines are natural immune stimulants, which cannot be used widely due to their short half-lives and narrow therapeutic windows. AskGene uses its proprietary technology of SmartKine to overcome these challenges. We already have on-going clinical studies of ASKG315 (an IL-15 prodrug) and an IL-2 prodrug through a partnership. With ASKG915, we expand our platform to include a molecule that should produce both full anti-PD-1 and IL-15 effects. Such molecules may be able to treat both patients who have failed anti-PD-1 treatment, as well as those who need the extra boost of IL-15 to achieve a response to checkpoint inhibitor therapy. FIH dosing of ASKG915 is an important milestone towards making this next-generation immunotherapy available to patients in need. We are very excited about the progress made so far and look forward to the upcoming POC data from our clinical studies in the future."
About ASKB915
ASKG915 is the world’s first anti-PD-1 antibody / IL-15 prodrug fusion molecule to enter clinical development. The molecule can achieve tumor targeting through the anti-PD-1 antibody and be locally activated at the tumor site. It is also designed to allow a high enough dose so that the anti-PD-1 antibody has full PD-1 blockage functionality. Preclinical data showed that ASKG915 has extended PK, significantly better efficacy than anti-PD-1 antibody monotherapy, and an expanded therapeutic window. ASKG915 is expected to benefit patients who are not responding to current anti-PD-1 antibody therapies. A multi-regional phase I clinical trial in the US and China was started in Aug 2023.